ONTX
Corgi ONTO 2x Daily ETF
Set alert
- YTD
- -71.65%
- 1 year
- -71.65%
- Open
- 7.13
- Prev close
- 8.96
- Mkt cap
- 20.90M
- Vol
- 26.66K
- Avg vol
- 12.90K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.91
- High
- 7.71
- Forward P/E
- -1.16
- Beta
- 1.35
- Short ratio
- 0.19
- Inst. own
- 7.95%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 20, 2024
- 50-d avg
- 0.815224
- 200-d avg
- 0.783364
- 1y target
- 8.33
Key statistics
- Market cap
- 20.90M
- Enterprise value
- -4.87M
- Trailing P/E
- 0.00
- Forward P/E
- -1.16
- PEG ratio
- 0.00
- Price / sales
- 92.50
- Price / book
- 1.44
- EPS (TTM)
- -0.96
- Beta
- 1.35
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 226.00K
- Revenue growth
- 0.00%
- Free cash flow
- -10.47M
- Total cash
- 25.24M
- Total debt
- 0
- Return on equity
- -84.30%
- Shares outstanding
- 21.00M
- Short % of float
- 0.10%
- 50-day average
- 0.815224
- 200-day average
- 0.783364
Analyst view
Consensus: buy
- Target (low)
- 7.00
- Target (mean)
- 8.33
- Target (high)
- 11.00
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
May 20, 2024
Expected May 20, 2024. Consensus EPS estimate -0.23.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 20, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | -0.26 | — | — | — |
| Aug 10, 2023 | Jun 1, 2023 | -0.29 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | -0.27 | — | — | — |
| Mar 16, 2023 | Dec 1, 2022 | -0.27 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 11, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 10, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 13, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Jun 5, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| May 24, 2023 | HC Wainwright & Co. | reit | — | Buy |
| May 15, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Corgi ONTO 2x Daily ETF
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- onconova.com
News
- Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
- Earnings Scheduled For November 14, 2023
- Earnings Scheduled For August 10, 2023
- Earnings Scheduled For May 15, 2023
- Why SAP Shares Are Trading Higher By Around 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session
- Earnings Scheduled For March 16, 2023
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Stocks That Hit 52-Week Lows On Tuesday
Your note
Sign in to keep a note on ONTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| 683 CAPITAL MANAGEMENT L L C | Beneficial Owner of more than 10% of a Class of Security | Sale | Sep 17, 2019 | 0 |
| ARMISTICE CAPITAL L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Sep 22, 2019 | 0 |
| BIENEN HENRY S | Director | Conversion of Exercise of derivative security | Jul 28, 2016 | 8,914 |
| FRUCHTMAN STEVEN M | Officer | Conversion of Exercise of derivative security | Jul 28, 2016 | 6,376 |
| GUERIN MARK PATRICK | Officer | Conversion of Exercise of derivative security | Jul 28, 2016 | 3,726 |
| HOFFMAN MICHAEL B | Director | Sale | Aug 26, 2020 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.38% | 708,618 | 836.17K | Jun 29, 2023 |
| Blackrock Inc. | 1.19% | 248,881 | 293.68K | Jun 29, 2023 |
| Renaissance Technologies, LLC | 1.12% | 234,674 | 276.92K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.81% | 169,501 | 200.01K | Jun 29, 2023 |
| Two Sigma Investments, LP | 0.75% | 157,798 | 186.20K | Jun 29, 2023 |
| Two Sigma Advisers, LP | 0.68% | 143,339 | 169.14K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.74% | 365,661 | 431.48K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 1.53% | 321,970 | 379.92K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.39% | 81,912 | 95.84K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.16% | 33,198 | 38.84K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.11% | 23,169 | 27.11K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.10% | 21,108 | 24.70K | May 30, 2023 |